Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03883763
Other study ID # CRT090
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date April 1, 2022
Est. completion date November 30, 2023

Study information

Verified date July 2022
Source Cristália Produtos Químicos Farmacêuticos Ltda.
Contact João B Garcia, MD/PhD
Phone +559888020622
Email jbgarcia@uol.com.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind, active-controlled study to evaluate the non-inferiority of hyperbaric Novabupi® versus hyperbaric Neocaine® in spinal anesthesia in lower limbs vascular surgery. The schedule consists of four visits: screening (visit 1); pre-anesthetic evaluation and randomization (visit 2); treatment (visit 3) and discharge from study (visit 4).


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date November 30, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Provision of written informed consent - Both sexes - Age between 18 and 80 years, inclusive - ASA category I or II - Indication of spinal anesthesia for varicose vein surgery in lower limbs with a maximum duration of 3 hours. Exclusion Criteria: - Contraindications to spinal anesthesia - Hypersensitivity or intolerance to local anesthetics or to the components of formula - Use of any anticoagulant, regardless of type until 60 days before entering the study - Spinal cord injuries, peripheral neuropathies or any other neurological conditions leading to sensory and / or motor disorders - Dementia, mental retardation and other major cognitive changes - Obesity with body mass index (BMI) > 30 or difficulty in performing the puncture - Anatomical difficulty in the spine in the opinion of the Investigator that can make puncture difficult - Any previous surgical intervention of the spine - Tattoo at the puncture site - Participants with a history of alcohol or illicit drug abuse, as defined by Diagnostic and Statistical Manual of Mental Disorders, 5th edition - Pernicious anemia - History of severe anaphylactic reactions or Steven-Johnson disease - Changes in safety exams (applicable at the time of randomization): - International Normalized Ratio = 1.4 - Hemoglobin < 10 g / dL - Platelet count <100,000 / mm3 - Glycemia> 200 mg / dL - Bradyarrhythmias: heart block with clinical repercussion in the investigator's opinion - Maximum of eight ventricular extrasystoles per minute, evident on the ECG - Pregnancy or lactation - Any other condition that, in the opinion of the Investigator, may lead to an increased risk for the participant.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
bupivacaine S75:R25 plus 8% glucose
Spinal anesthesia, 20 mg
bupivacaine S50:R50 plus 8% glucose
Spinal anesthesia, 20 mg

Locations

Country Name City State
Brazil CEPEC São Luís Maranhão

Sponsors (1)

Lead Sponsor Collaborator
Cristália Produtos Químicos Farmacêuticos Ltda.

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison between arms from latency to T10 dermatome sensitive block Time elapsed between the withdrawal of the needle at the end of the injection of the local anesthetic and the absence of response to sensorial stimuli in the region corresponding to the T10 dermatome 20 minutes
Primary Comparison between arms from the duration of the sensory block Time elapsed between the withdrawal of the needle at the end of the local anesthetic injection and the presence of positive sensitivity by needle stimulation in the L5 dermatome 24 hours
Secondary Comparison between arms from the degree of motor blockage when blocking T10 sensitive The motor block will be evaluated by the modified Bromage scale. The degree of motor block will be assessed when the sensory block reaches T10.
The motor block will be evaluated every 5 minutes from the end of the anesthetic injection (time 0) through the modified Bromage scale:
0 = without motor block,
1 = blocked hip,
2 = blocked hip and knee,
3 = blocked hip, knee and ankle.
Will be recorded:
the degree of motor blockage when the sensory block reaches T10,
the time to reach the maximum block,
time for full recovery (Bromage score 0).
20 minutes
Secondary Comparison between arms from the duration of the motor block Duration of motor block will be considered as the time interval between needle withdrawal after puncture and return to score 0 on the modified Bromage scale. Time will be recorded to reach grade 3 motor block and at the end of surgery. During anesthesia recovery, evaluations will be performed every 15 minutes 24 hours
Secondary Comparison between arms from the highest level of sensory block 3 hours
Secondary Comparison between arms from the time to reach the highest level of sensory block 1 hour
Secondary Comparison between arms from the time for the 4-segment regression of the sensory block The height of the sensitive block will be evaluated every 5 minutes until the maximum level is reached. From this point, the height of the block will be evaluated every 10 minutes until the regression of 4 levels 3 hours
Secondary Comparison between arms of respiratory and cardiovascular safety Evidenced by the incidence, severity and causality of clinically significant SpO2 changes.
Every 5 minutes SpO2 will be recorded until completing 60 minutes, every 10 minutes until completing 120 minutes, every 20 minutes until 12 hours.
12 hours
Secondary Comparison between arms of cardiovascular safety Evidenced by the incidence, severity and causality of clinically significant changes in blood pressure measured automatically by cardiac monitoring.
Every 5 minutes blood pressure will be recorded until completing 60 minutes, every 10 minutes until completing 120 minutes, every 20 minutes until completing 180 minutes and every 30 minutes until complete recovery of the motor function.
24 hours
Secondary Comparison between arms of cardiovascular safety Evidenced by the incidence, severity and causality of clinically significant changes in heart rate measured automatically by cardiac monitoring.
Every 5 minutes heart rate will be recorded until completing 60 minutes, every 10 minutes until completing 120 minutes, every 20 minutes until completing 180 minutes and every 30 minutes until complete recovery of the motor function
12 hours
Secondary Comparison between arms from the percentage of motor and sensory block failure After the needle has been withdrawn, the anesthetic should be installed for up to 20 minutes. If no sensory and / or motor blockage is observed after this period, the Investigator will indicate that there was an anesthetic failure that should be classified as:
A. total block failure (absence of anesthesia in sensory and motor aspects with preserved sensitivity of the perineal region) B. partial failure (when any area below the T10 dermatome shows signs of analgesia or motor block, but surgery can not be performed, requiring intense sedation or general anesthesia).
In case of failure, the participant will be immediately discontinued from the study and the surgery will normally proceed with anesthetic procedure at the discretion of the Investigator. Anesthesia failure should be reported as an adverse event.
20 minutes
Secondary Comparison between arms from the occurrence of adverse events Adverse event information will be collected from all participants on all visits 7 days
See also
  Status Clinical Trial Phase
Completed NCT02565303 - Minimum Effective Dose of Ropivacaine for Spinal Anesthesia for Cesarean Delivery N/A
Recruiting NCT03248817 - Phenylephrine Infusion in Cesarean Delivery Phase 4
Completed NCT02840006 - Spinal Anesthesia Associated With General Anesthesia in Coronary Artery Bypass Phase 4
Completed NCT01624844 - Predictive Value of Ultrasound Measurement of the Dural Sac Volume on the Sensory Level in Spinal Anesthesia N/A
Recruiting NCT00974961 - Levobupivacaine on Heart Rate Variability (HRV) in Spinal Anesthesia Phase 4
Recruiting NCT00492453 - Spinal Versus General Anesthesia for Laparoscopic Cholecystectomy N/A
Completed NCT05549011 - PENG vs SIFI Block for Positioning Pain During Spinal Anesthesia
Completed NCT03805503 - Chloroprocaine for Inguinal Herniorrhaphy Phase 4
Completed NCT03775655 - Low Dose Hyperbaric Bupivacaine and Dexmedetomidine as an Adjuvant, Caesarean Section Phase 2/Phase 3
Completed NCT03199170 - Effect of Bilateral Quadratus Lumborum Block for Pain Relief in Patients With Cesarean Section N/A
Completed NCT03302039 - Three Protocols for Phenylephrine Administration in Cesarean Delivery Phase 4
Not yet recruiting NCT05063292 - Effect of Prewarming On Skin Temperature Changes N/A
Not yet recruiting NCT05583214 - Evaluating the Effectiveness of Ondansetron Versus Dexamethasone Versus Placebo for the Control of Intraoperative Nausea and Vomiting in Patients Undergoing Lower-segment Caesarean Section Under Spinal Anesthesia Phase 4
Recruiting NCT02937792 - Large Volume Bupivacaine 0.5% Versus Small Volume in Elective Caesarean Section N/A
Recruiting NCT01415284 - ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia Phase 4
Completed NCT00537472 - Low Dose Spinal Bupivacaine for Total Knee Replacement and Recovery Room Wait Time N/A
Completed NCT05548985 - Midodrine for Prophylaxis Against Post Spinal Hypotension in Elderly Population N/A
Completed NCT03322098 - Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Geriatric Patients Undergoing Total Knee Replacement Under Spinal Anesthesia N/A
Recruiting NCT04598061 - IV Dexmedetomidine as Spinal Anesthesia Adjuvant in Infants
Completed NCT04083768 - Effect of Different Left Lateral Table Tilt for Elective Cesarean Delivery Under Spinal Anesthesia N/A